lactic acid has been researched along with Non-alcoholic Fatty Liver Disease in 16 studies
Lactic Acid: A normal intermediate in the fermentation (oxidation, metabolism) of sugar. The concentrated form is used internally to prevent gastrointestinal fermentation. (From Stedman, 26th ed)
2-hydroxypropanoic acid : A 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group.
Non-alcoholic Fatty Liver Disease: Fatty liver finding without excessive ALCOHOL CONSUMPTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Non-alcoholic fatty liver disease (NAFLD) is the most common cause of liver disease in developed countries." | 1.48 | Modelling non-alcoholic fatty liver disease in human hepatocyte-like cells. ( Blanco, GR; Cameron, K; Cartier, J; Drake, AJ; Dunn, WB; Hay, DC; Lyall, MJ; Meehan, RR; Meseguer-Ripolles, J; O'Duibhir, E; Szkolnicka, D; Thomson, JP; Villarin, BL; Wang, Y, 2018) |
| " Silymarin is a potent hepatoprotective agent; however, it has low oral bioavailability due to its poor aqueous solubility and low membrane permeability." | 1.48 | Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD. ( Fan, Q; Feng, N; Huang, P; Jiang, Z; Li, Z; Liang, J; Liu, J; Liu, Y; Wang, Z; Yan, F, 2018) |
| "steatosis grade 3 or steatohepatitis with or without beginning fibrosis frequently show altered fecal microbiota composition and elevated bacterial endotoxin levels." | 1.46 | Markers of intestinal permeability are already altered in early stages of non-alcoholic fatty liver disease: Studies in children. ( Bergheim, I; Engstler, AJ; Maier, IB; Nier, A, 2017) |
| "Non-alcoholic fatty liver disease (NAFLD) is a major risk factor leading to chronic liver disease and type 2 diabetes." | 1.43 | Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease. ( Auvinen, P; Gastaldelli, A; Hyötyläinen, T; Jäntti, S; Jerby, L; Mattila, I; Orešič, M; Petäjä, EM; Ruppin, E; Yki-Järvinen, H, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (68.75) | 24.3611 |
| 2020's | 5 (31.25) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, G | 1 |
| Dai, Y | 1 |
| Yan, Y | 1 |
| Zheng, X | 1 |
| Zhang, H | 1 |
| Li, H | 2 |
| Chen, W | 1 |
| Ma, YL | 1 |
| Ke, JF | 1 |
| Wang, JW | 1 |
| Wang, YJ | 1 |
| Xu, MR | 1 |
| Li, LX | 1 |
| Sarkar, S | 1 |
| Saha, P | 1 |
| Seth, RK | 1 |
| Mondal, A | 1 |
| Bose, D | 1 |
| Kimono, D | 1 |
| Albadrani, M | 1 |
| Mukherjee, A | 1 |
| Porter, DE | 1 |
| Scott, GI | 1 |
| Xiao, S | 1 |
| Brooks, B | 1 |
| Ferry, J | 1 |
| Nagarkatti, M | 1 |
| Nagarkatti, P | 1 |
| Chatterjee, S | 1 |
| Lin, H | 1 |
| Zhu, L | 1 |
| Baker, SS | 1 |
| Baker, RD | 1 |
| Lee, T | 1 |
| Wang, T | 1 |
| Chen, K | 1 |
| Yao, W | 1 |
| Zheng, R | 1 |
| He, Q | 1 |
| Xia, J | 1 |
| Li, J | 1 |
| Shao, Y | 1 |
| Zhang, L | 1 |
| Huang, L | 1 |
| Qin, L | 1 |
| Xu, M | 1 |
| Zhang, Z | 1 |
| Pan, D | 1 |
| Li, Z | 2 |
| Huang, F | 1 |
| Nier, A | 1 |
| Engstler, AJ | 1 |
| Maier, IB | 1 |
| Bergheim, I | 1 |
| Liu, Q | 2 |
| Nassar, A | 1 |
| Buccini, L | 1 |
| Iuppa, G | 1 |
| Soliman, B | 1 |
| Pezzati, D | 1 |
| Hassan, A | 1 |
| Blum, M | 1 |
| Baldwin, W | 1 |
| Bennett, A | 1 |
| Chavin, K | 1 |
| Okamoto, T | 1 |
| Uso, TD | 1 |
| Fung, J | 1 |
| Abu-Elmagd, K | 1 |
| Miller, C | 1 |
| Quintini, C | 1 |
| Lyall, MJ | 1 |
| Cartier, J | 1 |
| Thomson, JP | 1 |
| Cameron, K | 1 |
| Meseguer-Ripolles, J | 1 |
| O'Duibhir, E | 1 |
| Szkolnicka, D | 1 |
| Villarin, BL | 1 |
| Wang, Y | 1 |
| Blanco, GR | 1 |
| Dunn, WB | 1 |
| Meehan, RR | 1 |
| Hay, DC | 1 |
| Drake, AJ | 1 |
| Liang, J | 1 |
| Liu, Y | 1 |
| Liu, J | 1 |
| Fan, Q | 1 |
| Jiang, Z | 1 |
| Yan, F | 1 |
| Wang, Z | 1 |
| Huang, P | 1 |
| Feng, N | 1 |
| Okubo, H | 1 |
| Nakatsu, Y | 1 |
| Sakoda, H | 1 |
| Kushiyama, A | 1 |
| Fujishiro, M | 1 |
| Fukushima, T | 1 |
| Matsunaga, Y | 1 |
| Ohno, H | 1 |
| Yoneda, M | 1 |
| Kamata, H | 1 |
| Shinjo, T | 1 |
| Iwashita, M | 1 |
| Nishimura, F | 1 |
| Asano, T | 1 |
| Hyötyläinen, T | 1 |
| Jerby, L | 1 |
| Petäjä, EM | 1 |
| Mattila, I | 1 |
| Jäntti, S | 1 |
| Auvinen, P | 1 |
| Gastaldelli, A | 1 |
| Yki-Järvinen, H | 1 |
| Ruppin, E | 1 |
| Orešič, M | 1 |
| Masania, J | 1 |
| Malczewska-Malec, M | 1 |
| Razny, U | 1 |
| Goralska, J | 1 |
| Zdzienicka, A | 1 |
| Kiec-Wilk, B | 1 |
| Gruca, A | 1 |
| Stancel-Mozwillo, J | 1 |
| Dembinska-Kiec, A | 1 |
| Rabbani, N | 1 |
| Thornalley, PJ | 1 |
| Lockman, KA | 1 |
| Htun, V | 1 |
| Sinha, R | 1 |
| Treskes, P | 1 |
| Nelson, LJ | 1 |
| Martin, SF | 1 |
| Rogers, SM | 1 |
| Le Bihan, T | 1 |
| Hayes, PC | 1 |
| Plevris, JN | 1 |
| Wang, L | 1 |
| Yan, X | 1 |
| Yu, C | 1 |
| Wei, H | 1 |
| Li, Y | 1 |
| Zhang, X | 1 |
| He, F | 1 |
| Jiang, Y | 1 |
| Botezelli, JD | 1 |
| Cambri, LT | 1 |
| Ghezzi, AC | 1 |
| Dalia, RA | 1 |
| Voltarelli, FA | 1 |
| de Mello, MA | 1 |
| Chan, IS | 1 |
| Guy, CD | 1 |
| Chen, Y | 1 |
| Lu, J | 1 |
| Swiderska-Syn, M | 1 |
| Michelotti, GA | 1 |
| Karaca, G | 1 |
| Xie, G | 1 |
| Krüger, L | 1 |
| Syn, WK | 1 |
| Anderson, BR | 1 |
| Pereira, TA | 1 |
| Choi, SS | 1 |
| Baldwin, AS | 1 |
| Diehl, AM | 1 |
1 review available for lactic acid and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Dicarbonyl stress in clinical obesity.
Topics: Animals; Diabetes Mellitus, Type 2; Humans; Lactic Acid; Lactoylglutathione Lyase; Mice; Non-alcohol | 2016 |
15 other studies available for lactic acid and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
The lactate receptor GPR81 mediates hepatic lipid metabolism and the therapeutic effect of metformin on experimental NAFLDs.
Topics: Animals; Carnitine O-Palmitoyltransferase; Fatty Acids; Lactic Acid; Lipid Metabolism; Liver; Metfor | 2022 |
Blood lactate levels are associated with an increased risk of metabolic dysfunction-associated fatty liver disease in type 2 diabetes: a real-world study.
Topics: Asian People; Diabetes Mellitus, Type 2; Humans; Lactic Acid; Metformin; Non-alcoholic Fatty Liver D | 2023 |
Higher intestinal and circulatory lactate associated NOX2 activation leads to an ectopic fibrotic pathology following microcystin co-exposure in murine fatty liver disease.
Topics: Animals; Cell Line; Enzyme Inhibitors; Fibrosis; Intestinal Mucosa; Intestines; Lactic Acid; Male; M | 2020 |
Secreted phosphoglucose isomerase is a novel biomarker of nonalcoholic fatty liver in mice and humans.
Topics: Adolescent; Animals; Biomarkers; Child; Child, Preschool; Glucose-6-Phosphate Isomerase; Hep G2 Cell | 2020 |
Acetylation of lactate dehydrogenase B drives NAFLD progression by impairing lactate clearance.
Topics: Acetylation; Acetyltransferases; Animals; Cell Line; Disease Progression; Hepatobiliary Elimination; | 2021 |
Markers of intestinal permeability are already altered in early stages of non-alcoholic fatty liver disease: Studies in children.
Topics: Acute-Phase Proteins; Adolescent; Alanine Transaminase; Carrier Proteins; Child; Endotoxins; Fatty L | 2017 |
Lipid metabolism and functional assessment of discarded human livers with steatosis undergoing 24 hours of normothermic machine perfusion.
Topics: Adult; Aged; Bile; Biomarkers; Cholesterol; Donor Selection; Female; Hemodynamics; Humans; Lactic Ac | 2018 |
Modelling non-alcoholic fatty liver disease in human hepatocyte-like cells.
Topics: Caprylates; Hepatocytes; Humans; Lactic Acid; Non-alcoholic Fatty Liver Disease; Pyruvic Acid; Trans | 2018 |
Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD.
Topics: Administration, Oral; Animals; Biological Availability; Biological Transport; Caco-2 Cells; Chitosan | 2018 |
Mosapride citrate improves nonalcoholic steatohepatitis with increased fecal lactic acid bacteria and plasma glucagon-like peptide-1 level in a rodent model.
Topics: Animals; Benzamides; Choline Deficiency; Feces; Gastrointestinal Tract; Glucagon-Like Peptide 1; Inf | 2015 |
Genome-scale study reveals reduced metabolic adaptability in patients with non-alcoholic fatty liver disease.
Topics: Adaptation, Physiological; Adult; Blood Glucose; Case-Control Studies; Female; Gene Expression Profi | 2016 |
Proteomic profiling of cellular steatosis with concomitant oxidative stress in vitro.
Topics: Aldehyde Reductase; Aldo-Keto Reductases; Ammonia; Caprylates; Cell Line, Tumor; Cholesterol; Fatty | 2016 |
A proton nuclear magnetic resonance metabonomics approach for biomarker discovery in nonalcoholic fatty liver disease.
Topics: Adult; Animals; Biomarkers; Blood Glucose; Diet; Fatty Liver; Female; Glutamic Acid; Humans; Lactic | 2011 |
Fructose-rich diet leads to reduced aerobic capacity and to liver injury in rats.
Topics: Alanine Transaminase; Animals; Area Under Curve; Aspartate Aminotransferases; Blood Glucose; Catalas | 2012 |
Paracrine Hedgehog signaling drives metabolic changes in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cells, Cultured; Fatty Liver; Glycolysis; Hedgehog Proteins; Hep | 2012 |